US FDA grants orphan drug designation to HanchorBio’s HCB101 to treat gastric cancer: Taipei, Shanghai Monday, February 16, 2026, 17:00 Hrs [IST] HanchorBio, Inc., a global clin ...

CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to ...

CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate ...

A feature of pancreatic cancer cells' surroundings determines whether they grow fast or become resistant to chemotherapy, a ...

HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies. While trastuzumab deruxtecan has shown superior activity ...

Gastric cancer remains the fifth leading cause of cancer-related deaths worldwide. Although its overall incidence has declined, early-onset cases—diagnosed before age 50—display unique biological and ...

Precancerous colorectal lesions, or dysplasia, in patients with inflammatory bowel disease (IBD) confer markedly different risks of future colorectal cancer depending on dysplasia grade, according to ...

The Dubai-headquartered world’s number one diplomatic supply company last Friday completed an extraordinary team effort to support #KickCancerThon, the travel retail industry-wide visibility and ...